AKBA (STOCKS)
Akebia Therapeutics, Inc.
$1.485000
-0.025000 (-1.66%)
Prev close: $1.510000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- John P. Butler
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $428.09M
- Employees
- 181
- P/E (TTM)
- -19.84
- P/B (TTM)
- 9.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.00 | $-0.02 | +0.0179 | +100.00% |
|
Jun 2025 (Q2)
|
$0.00 | $-0.02 | +0.0204 | +100.00% |
|
Mar 2025 (Q1)
|
$0.03 | $-0.05 | +0.0759 | +165.36% |
|
Dec 2024 (Q4)
|
$-0.10 | $-0.08 | -0.0184 | -22.55% |
Financial Statements
| Revenues | $225.07M |
| Benefits Costs and Expenses | $240.36M |
| Cost Of Revenue | $47.29M |
| Costs And Expenses | $240.36M |
| Gross Profit | $177.78M |
| Operating Expenses | $160.03M |
| Selling, General, and Administrative Expenses | $109.07M |
| Research and Development | $47.50M |
| Other Operating Expenses | $3.47M |
| Operating Income/Loss | $17.75M |
| Income/Loss From Continuing Operations After Tax | -$15.91M |
| Income/Loss From Continuing Operations Before Tax | -$15.29M |
| Net Income/Loss | -$15.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$15.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$15.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.08 |
| Diluted Earnings Per Share | -$0.08 |
| Basic Average Shares | 765,452,631 |
| Diluted Average Shares | 789,682,574 |
| Assets | $364.15M |
| Current Assets | $258.34M |
| Inventory | $18.64M |
| Prepaid Expenses | $0.00 |
| Other Current Assets | $239.69M |
| Noncurrent Assets | $105.82M |
| Fixed Assets | $1.47M |
| Other Non-current Assets | $104.34M |
| Liabilities | $322.56M |
| Current Liabilities | $133.38M |
| Accounts Payable | $10.09M |
| Wages | $9.32M |
| Other Current Liabilities | $113.98M |
| Noncurrent Liabilities | $189.18M |
| Long-term Debt | $47.64M |
| Other Non-current Liabilities | $141.54M |
| Equity | $41.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $41.59M |
| Liabilities And Equity | $364.15M |
| Net Cash Flow From Operating Activities | $32.40M |
| Net Cash Flow From Operating Activities, Continuing | $32.40M |
| Net Cash Flow From Investing Activities | -$51.00K |
| Net Cash Flow From Investing Activities, Continuing | -$51.00K |
| Net Cash Flow From Financing Activities | $100.10M |
| Net Cash Flow From Financing Activities, Continuing | $100.10M |
| Net Cash Flow | $132.45M |
| Net Cash Flow, Continuing | $132.45M |
| Comprehensive Income/Loss | -$15.91M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$15.91M |
| Other Comprehensive Income/Loss | -$15.91M |